Wearable pump allows treatment of worsening HF at home

In patients admitted to the hospital with worsening HF, an early discharge strategy involving treatment at home with subcutaneous furosemide via a pump was linked to more days alive and out of the hospital compared with standard care.
For the SUBCUT HF II trial, presented at Heart Failure 2026, researchers randomly assigned 172 patients with worsening HF (mean age, 71 years; 29% women; mean left ventricular ejection fraction, 36%) admitted to the hospital for IV diuretics for congestion to standard care or an early discharge strategy using subcutaneous furosemide (Lasix ONYU, SQ Innovation)







